A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Published 2013 View Full Article

Authors

Keywords

Journal

GYNECOLOGIC ONCOLOGY

Volume 132, Issue 3, Pages 526-530

Publisher

Elsevier BV

Online

2013-12-19

DOI

10.1016/j.ygyno.2013.12.018

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

GYNECOLOGIC ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Ask a Question. Answer a Question.